ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP28-23 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective June 1, 2023
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 951 - 960 လၢ 4179 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP29-23 Blue Cross Preferred Genetic Laboratory Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP30-23 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective May 1, 2023
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP31-23 Commercial Pharmacy Benefit Exclusion for Fluticasone-Salmeterol
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP32-23 Review and Update NPI Information
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP33-23 Provider Survey: Training & Development Focusing on Equity in Health Care
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP34-23 Update for New to Market Medical Drugs: Tofersen
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP35-23 Notice of Correction to Ambulance Mileage Reimbursement
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
တၢ်န့ၢ်ဘျုးဒီးတၢ်ဟ့ၣ်အဘူးအလဲ
BlueRide Parent or Guardian Ride Consent Form
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P17-23 Inflation Reduction Act (IRA): Part B Rebatable Drugs and Part B Insulin Cap
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 03, 2023